BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29477396)

  • 1. ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.
    Perfetto EM
    Value Health; 2018 Feb; 21(2):169-170. PubMed ID: 29477396
    [No Abstract]   [Full Text] [Related]  

  • 2. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.
    Burkholder R; Dougherty JS; Neves LA
    Value Health; 2018 Feb; 21(2):173-175. PubMed ID: 29477398
    [No Abstract]   [Full Text] [Related]  

  • 3. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
    Sculpher M
    Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
    [No Abstract]   [Full Text] [Related]  

  • 4. ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.
    Solow B; Pezalla EJ
    Value Health; 2018 Feb; 21(2):166-168. PubMed ID: 29477395
    [No Abstract]   [Full Text] [Related]  

  • 5. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
    Garrison LP; Pauly MV; Willke RJ; Neumann PJ
    Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making.
    Norman R; Chalkidou K; Culyer AJ
    Value Health; 2018 Feb; 21(2):117-118. PubMed ID: 29477387
    [No Abstract]   [Full Text] [Related]  

  • 12. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
    Phelps CE; Lakdawalla DN; Basu A; Drummond MF; Towse A; Danzon PM
    Value Health; 2018 Feb; 21(2):146-154. PubMed ID: 29477392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
    Garrison LP; Neumann PJ; Willke RJ
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reflections: NICE, health economics, and outcomes research.
    Rawlins M
    Value Health; 2012 May; 15(3):568-9. PubMed ID: 22583468
    [No Abstract]   [Full Text] [Related]  

  • 17. As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?
    Dubois RW; Westrich K
    Value Health; 2019 Sep; 22(9):977-980. PubMed ID: 31511186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
    Berger ML
    J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.